HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

JV 1-52

Subscribe to New Research on JV 1-52

Also Known As:

JV-1-52

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Groot, Kate: 1 article (04/2002)
2.	Krupa, Magdalena: 1 article (04/2002)
3.	Halmos, Gabor: 1 article (04/2002)
4.	Plonowski, Artur: 1 article (04/2002)
5.	Schally, Andrew V: 1 article (04/2002)
6.	Varga, Jozsef L: 1 article (04/2002)
7.	Varga, J L: 1 article (11/2001)
8.	Schally, A V: 1 article (11/2001)
9.	Chatzistamou, I: 1 article (11/2001)
10.	Armatis, P: 1 article (11/2001)

Related Diseases

1.	Carcinoma (Carcinomatosis) 04/01/2002 - "In our study, nude mice bearing PC-3 human androgen-independent prostate carcinomas were treated with JV-1-52 or JV-1-53 (20 microg/day, s.c.) for 28 days. " 11/01/2001 - "In the present study we investigated the effects of GH-RH antagonist JV-1-36 and VIP antagonist JV-1-52, on the growth and tumorigenicity of UCI-107 ovarian cell carcinoma xenografted into nude mice. "
2.	Neoplasms (Cancer) 11/01/2001 - "All ten mice injected with cells treated with medium alone developed tumors within 23 days after cell inoculation, while only eight of ten and four of ten mice injected with cells exposed to JV-1-36 or JV-1-52, respectively, had tumors. " 11/01/2001 - "The concentration of IGF-II in tumors was reduced by 66% in the JV-1-36-treated group and by 62% in the group given JV-1-52 (both P < 0.05). " 11/01/2001 - "After 22 days of therapy with JV-1-36 or JV-1-52 at the dose of 20 microg/day, the final volume of UCI-107 tumors was significantly (P<0.05) decreased by 50.5% and 56%, respectively, compared to controls. "

Related Drugs and Biologics

1.	JV 1-53
2.	JV 1-36
3.	Insulin-Like Growth Factor II (Somatomedin A)